InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Results from Phase II Binge Eating Disorder Clinical Trial

Jun 9, 2022

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced the results gathered from the first patient dosed in its phase II STOP clinical trial. According to the announcement, initial data indicates that psilocybin and psilocybin-related compounds such as Tryp’s TRP-8802 have potential for the treatment of binge eating disorder (“BED”). The trial, titled STOP for Study of the Treatment of Overeating utilizing Psilocybin, is being conducted in collaboration with the University of Florida and is the first use of psilocybin in conjunction with psychotherapy as a therapeutic intervention in patients with BED. Specific results show that immediately following the post-dosing integration session with the trial’s psychotherapists and continuing throughout the four-week time period post dosing, the first patient in the STOP trial exhibited significant results, including reduced overall anxiety, reduced anxiety around food, reduced compulsion to overeat, and improved self-image and confidence; in addition, there were no drug-related adverse events observed throughout the four-week period. These results align with those seen in similar clinical studies. The patient will continue to be monitored for an additional eight weeks. “While we are mindful to not draw too many conclusions from the first patient at four weeks, we are excited with the results to date and look forward to the potential replication of these results in additional patients,” said Tryp interim CEO and chief scientific officer Jim Gilligan in the press release. “Based on our understanding of psychotherapy in BED patients and our discussions with our colleagues at the University of Florida, we believe that the improvements witnessed in this patient following a single intervention with TRP-8802 in combination with tailored psychotherapy are on par with what might be possible in 12 months of extensive psychotherapy alone.”

To view the full release, visit https://ibn.fm/wvOkP

About Tryp Therapeutics Inc.

Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric-Disorders, or PFN(TM) (“PFN”), program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain and other indications. The company has begun enrolling patients in its phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience. For more information about the company, please visit www.TrypTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

More News

article.head.headline
Nov 19, 2026
Post Malone digs into the Stoney vault with 8 unreleased songs for 10th anniversary edition

Post Malone is celebrating 10 years of Stoney by releasing previously unheard tracks from the album's era and staging a special one-night-only anniversary concert in Los Angeles.

article.head.headline
Nov 19, 2026
Florence Pugh hails 'unbelievably talented' Robert Pattinson

Florence Pugh has heaped praise on Robert Pattinson, after he was announced as the new James Bond.

article.head.headline
Nov 19, 2026
Kim Kardashian 'buys SKIMS dupes' on TikTok

Reality star Kim Kardashian has revealed that she avidly shops on TikTok.

article.head.headline
Nov 19, 2026
Derek Hough felt 'guilt' after wife Hayley Erbert's health crisis

Derek Hough was overwhelmed with "guilt" when wife Hayley Erbert needed emergency surgery following a bleed on her skull back in 2023.

article.head.headline
Nov 19, 2026
AJ McLean back with estranged wife

AJ McLean has reunited with his estranged wife, Rochelle Karidis.

article.head.headline
Nov 19, 2026
Maika Monroe wants to play another evil character

Maika Monroe has revealed that she'd love to play another evil character.

article.head.headline
Nov 19, 2026
Gemma Chan wants to be Robert Pattinson's Bond Girl: 'Absolutely I would'

Gemma Chan has been asked about the possibility of joining the James Bond franchise, and she is "flattered" by fans linking her to a potential Bond Girl role.

article.head.headline
Nov 19, 2026
Kaitlin Butts recalls being 'blown away' by Dolly Parton

Kaitlin Butts has heaped praise on Dolly Parton, who passed away in August, aged 80.

article.head.headline
Nov 19, 2026
Mumford and Sons felt like wedding crashers making CMA Awards debut

Marcus Mumford has reflected on his band's first ever appearance at the CMA Awards in Nashville.

article.head.headline
Nov 19, 2026
Bugs bassist Jordan Brunoli dies following terminal colorectal cancer diagnosis

The Aussie musician was diagnosed with stage four colorectal cancer in 2025.

article.head.headline
Nov 19, 2026
Dolly Parton 'is with the angels', says Lainey Wilson

Lainey Wilson has paid a glowing tribute to Dolly Parton, who passed away in August.

article.head.headline
Nov 19, 2026
Beloved character actor Larry Poindexter has died aged 66 after being hit by a car

Larry Poindexter, whose credits include General Hospital, Days of Our Lives and S.W.A.T., was crossing the street to get some food in his Studio City neighbourhood.


YOUR NEWS, OUR NETWORK.

Do you have Great News you want to tell the world?

Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.

E-Stardom

E-Stardom is the exclusive online news network for breaking entertainment news. We bring to you the premium coverage and fashion tips to your favorite celebrity style. Get your daily celebrity news fix only here in E-Stardom.